Amicus Therapeutics (LTS:0HF9) Margin of Safety % (DCF Earnings Based) : N/A (As of Jun. 20, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Amicus Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Amicus Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of Amicus Therapeutics's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, Amicus Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amicus Therapeutics's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Amicus Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.

Amicus Therapeutics Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Amicus Therapeutics (LTS:0HF9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (LTS:0HF9) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

FOLD:USA AM6:Germany AM6:Germany

Address

3675 Market Street, Philadelphia, PA, USA, 19104

Website

https://www.amicusrx.com

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics (LTS:0HF9) Headlines

No Headlines